{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:48:53Z","timestamp":1788461333467,"version":"build-2803163510"},"reference-count":144,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Dupilumab, a standard treatment for atopic dermatitis (AD), has been associated with cutaneous T\u2010cell lymphomas (CTCL), particularly mycosis fungoides (MF) and S\u00e9zary syndrome (SS). Nevertheless, the available data remain heterogeneous.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To characterize the clinical features, timeline and outcomes of dupilumab\u2010related CTCL emergence in order to develop consensus\u2010based recommendations for dupilumab use in CTCL\u2010related settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was conducted involving 51 studies reporting cases of CTCL in patients treated with dupilumab, followed by a modified delphi process to generate expert consensus recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data were obtained from 547 patients (mean age: 58\u2009years; SD: 11.5; range: 10\u201385). New or worsening skin lesions were reported after dupilumab initiation, occurring at a mean of 8.9\u2009months (SD 5.1; range 0.5\u201327\u2009months). These were diagnosed as MF in 72% of cases, SS in 11% and other CTCL subtypes in 19%, of which 53% were at an early stage (stage \u2264IIA). Dupilumab was discontinued in 75% of cases, and 62% received CTCL\u2010directed treatment. Clinical remission was achieved in 44 of the 63 patients with available follow\u2010up. The expert panel reached broad consensus, agreeing that dupilumab may unmask or exacerbate pre\u2010existing CTCL and should be avoided in cases of MF\/SS and mogamulizumab\u2010induced rashes. They emphasized the importance of diagnostic vigilance, providing recommendations for skin biopsy, histology and clonality testing before and during treatment, particularly for patients with AD onset after the age of 40 or with atypical features. Dupilumab should be discontinued once CTCL confirmed, and methotrexate or phototherapy considered as alternatives. Cyclosporine and JAK inhibitors are considered unsuitable, and switching to other Th2\u2010targeting biologics is discouraged due to insufficient data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dupilumab may unmask or exacerbate CTCL, particularly MF and SS. The consensus\u2010based recommendations offer practical guidance for the safe management of patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70407","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:48:01Z","timestamp":1773384481000},"page":"1344-1358","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cutaneous T\u2010cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8934-9174","authenticated-orcid":false,"given":"Florent","family":"Amatore","sequence":"first","affiliation":[{"name":"Department of Dermatology, North Hospital, Assistance\u2010Publique H\u00f4pitaux de Marseille, INSERM U1068 Aix\u2010Marseille University  Marseille France"},{"name":"French Cutaneous Lymphoma Group (GFELC) From Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie (SFD)  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Neildez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, CHU Rennes, Univ Rennes, Inserm, EHESP Irset (Institut de Recherche en sant\u00e9, Environnement et Travail) UMR_S  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7828-6211","authenticated-orcid":false,"given":"Ad\u00e8le","family":"de Masson","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphoma Group (GFELC) From Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie (SFD)  Paris France"},{"name":"Department of Dermatology, Saint\u2010Louis University Hospital, AP\u2010HP, Universit\u00e9 Paris Cit\u00e9, INSERM U1342 Institut de Recherche Saint\u2010Louis  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Battistella","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphoma Group (GFELC) From Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie (SFD)  Paris France"},{"name":"Pathology Department H\u00f4pital Saint\u2010Louis, AP\u2010HP  Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM U1342, Institut de Recherche Saint\u2010Louis  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Tauber","sequence":"additional","affiliation":[{"name":"Groupe de Recherche sur L'ecz\u00e9ma ATopique (GREAT), from Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie (SFD)\u2010FRench Atopic DErmatitis Network (FRADEN) Network  Paris France"},{"name":"Department of Allergology and Clinical Immunology, Hospices Civils de Lyon, INSERM U1111, Centre International de Recherche en Infectiologie (CIRI) Lyon 1 University  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5383-7096","authenticated-orcid":false,"given":"Saskia","family":"Ingen\u2010Housz\u2010Oro","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphoma Group (GFELC) From Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie (SFD)  Paris France"},{"name":"Department of Dermatology Henri\u2010Mondor University Hospital, AP\u2010HP, Univ Paris Est Cr\u00e9teil, EpiDermE  Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6714-6643","authenticated-orcid":false,"given":"Catherine","family":"Droitcourt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, CHU Rennes, Univ Rennes, Inserm, EHESP Irset (Institut de Recherche en sant\u00e9, Environnement et Travail) UMR_S  Rennes France"},{"name":"Groupe de Recherche sur L'ecz\u00e9ma ATopique (GREAT), from Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie (SFD)\u2010FRench Atopic DErmatitis Network (FRADEN) Network  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Staumont\u2010Sall\u00e9","sequence":"additional","affiliation":[{"name":"Groupe de Recherche sur L'ecz\u00e9ma ATopique (GREAT), from Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie (SFD)\u2010FRench Atopic DErmatitis Network (FRADEN) Network  Paris France"},{"name":"Department of Dermatology, CHU de Lille, INSERM U1286 Inflammation Translational Research Institute (INFINITE), Univ Lille  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-1229","authenticated-orcid":false,"given":"Marie","family":"Beylot\u2010Barry","sequence":"additional","affiliation":[{"name":"French Cutaneous Lymphoma Group (GFELC) From Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie (SFD)  Paris France"},{"name":"Department of Dermatology, CHU de Bordeaux, BoRdeaux Institute of onCology (BRIC), INSERM U1312 University of Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.050"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.10.119"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16388"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.12.001"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20141"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.03.039"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/9924306"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-590398"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/life14020245"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.01.047"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000679"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604"},{"key":"e_1_2_13_14_1","unstructured":"PRISMA Guidelines [Internet]. Available from:https:\/\/www.prisma\u2010statement.org\/prisma\u20102020"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2017-110853"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011458"},{"key":"e_1_2_13_17_1","unstructured":"The Newcastle\u2010Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta\u2010analyses [Internet]. Available from:https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"e_1_2_13_18_1","unstructured":"STROBE [Internet]. Available from:https:\/\/www.strobe\u2010statement.org\/"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.090449"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1287\/mnsc.9.3.458"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17221"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2023.08.004"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034191"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2023.100128"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2068002"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9030303"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-55617-4_8"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.5070\/D3266049329"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2015.10.345"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1524293"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08934-0"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413388"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/12034754211027858"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00749-1"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2022.0096"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.09.002"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015064.pub2"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013206.pub2"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013513.pub3"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.17544"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23344"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom13040634"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.07.007"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14401"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2024.101006"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-024-05413-9"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2326480"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000845"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1939673"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2023.12.003"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17344"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.10.024"},{"issue":"2","key":"e_1_2_13_54_1","first-page":"9839","article-title":"Biologics and small molecules treatment for moderate\u2010to\u2010severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective","volume":"16","author":"Guglielmo A","year":"2023","journal-title":"Dermatol Rep [Internet]"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.009"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.051"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.12.013"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.878989"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.05.069"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.3846"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.05.041"},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.08.031"},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.091"},{"key":"e_1_2_13_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.100"},{"key":"e_1_2_13_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.104"},{"key":"e_1_2_13_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.105"},{"key":"e_1_2_13_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.08.082"},{"key":"e_1_2_13_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.076"},{"key":"e_1_2_13_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.099"},{"key":"e_1_2_13_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.08.015"},{"key":"e_1_2_13_71_1","doi-asserted-by":"publisher","DOI":"10.1080\/00016489.2024.2407402"},{"key":"e_1_2_13_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2024.02.011"},{"key":"e_1_2_13_73_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v101.224"},{"key":"e_1_2_13_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00895-2"},{"key":"e_1_2_13_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.09.012"},{"key":"e_1_2_13_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/cia2.12178"},{"key":"e_1_2_13_77_1","unstructured":"Lai.Single\u2010cell RNA sequencing defines molecular similarities between patch\/plaque\u2010stage mycosis fungoides and atopic dermatitis under dupilumab. Available from:https:\/\/www\u2010webofscience\u2010com.passerelle.univ\u2010rennes1.fr\/wos\/woscc\/full\u2010record\/WOS:001276879000091"},{"key":"e_1_2_13_78_1","unstructured":"Espinosa.Dupilumab is associated with disease worsening or unmasking of cutaneous T\u2010cell lymphoma. Available from:https:\/\/www\u2010webofscience\u2010com.passerelle.univ\u2010rennes1.fr\/wos\/woscc\/full\u2010record\/WOS:000574804200103"},{"key":"e_1_2_13_79_1","unstructured":"Fleischli.Dupilumab and other biologic therapies may influence the course and prognosis of cutaneous\u2010T cell lymphoma. Available from:https:\/\/www\u2010webofscience\u2010com.passerelle.univ\u2010rennes1.fr\/wos\/woscc\/full\u2010record\/WOS:001276879001028"},{"key":"e_1_2_13_80_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000001875"},{"key":"e_1_2_13_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-023-02652-z"},{"key":"e_1_2_13_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.047"},{"key":"e_1_2_13_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16764"},{"key":"e_1_2_13_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20053"},{"key":"e_1_2_13_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.08.057"},{"key":"e_1_2_13_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad277"},{"key":"e_1_2_13_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.06.1272"},{"key":"e_1_2_13_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.10.028"},{"issue":"2","key":"e_1_2_13_89_1","first-page":"77","article-title":"Long\u2010standing dermatitis treated with Dupilumab with subsequent progression to cutaneous T\u2010cell lymphoma","volume":"106","author":"Hollins LC","year":"2020","journal-title":"Cutis [Internet]"},{"key":"e_1_2_13_90_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.3849"},{"issue":"1","key":"e_1_2_13_91_1","article-title":"Two cases of mycosis fungoides diagnosed after treatment non\u2010response to dupilumab","volume":"27","author":"Newsom M","year":"2021","journal-title":"Dermatol Online J [Internet]"},{"key":"e_1_2_13_92_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3576"},{"key":"e_1_2_13_93_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3208"},{"key":"e_1_2_13_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13880"},{"issue":"4","key":"e_1_2_13_95_1","article-title":"Development of S\u00e9zary syndrome following the administration of dupilumab","volume":"26","author":"Tran J","year":"2020","journal-title":"Dermatol Online J [Internet]"},{"key":"e_1_2_13_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.15501"},{"key":"e_1_2_13_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17001"},{"issue":"3","key":"e_1_2_13_98_1","first-page":"131","article-title":"Cutaneous T\u2010cell lymphoma and concomitant atopic dermatitis responding to Dupilumab","volume":"106","author":"Mollanazar NK","year":"2020","journal-title":"Cutis [Internet]"},{"key":"e_1_2_13_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.12.010"},{"key":"e_1_2_13_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.05.037"},{"key":"e_1_2_13_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.09.020"},{"key":"e_1_2_13_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15079"},{"key":"e_1_2_13_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15290"},{"key":"e_1_2_13_104_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03330-y"},{"key":"e_1_2_13_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.04.023"},{"key":"e_1_2_13_106_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.2234"},{"key":"e_1_2_13_107_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2022.4279"},{"key":"e_1_2_13_108_1","doi-asserted-by":"publisher","DOI":"10.3390\/dermatopathology9040045"},{"key":"e_1_2_13_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.01.008"},{"key":"e_1_2_13_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16641"},{"key":"e_1_2_13_111_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05237-y"},{"issue":"2","key":"e_1_2_13_112_1","first-page":"105","article-title":"Diagnosis of mycosis Fungoides after Dupilumab treatment for atopic dermatitis","volume":"21","author":"O'Neill L","year":"2023","journal-title":"Skinmed"},{"key":"e_1_2_13_113_1","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_1090_2022"},{"key":"e_1_2_13_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.05.025"},{"issue":"8","key":"e_1_2_13_115_1","article-title":"Cutaneous T\u2010cell lymphoma progression: a potential Dupilumab pitfall","volume":"15","author":"Malick H","year":"2023","journal-title":"Cureus [Internet]"},{"key":"e_1_2_13_116_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_580_22"},{"issue":"2","key":"e_1_2_13_117_1","first-page":"184","article-title":"A case of S\u00e9zary syndrome in a patient treated with Dupilumab for atopic dermatitis","volume":"69","author":"Muramatsu K","year":"2024","journal-title":"Indian J Dermatol [Internet]"},{"key":"e_1_2_13_118_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2024.4729"},{"key":"e_1_2_13_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.02.009"},{"key":"e_1_2_13_120_1","doi-asserted-by":"publisher","DOI":"10.22543\/2392-7674.1506"},{"key":"e_1_2_13_121_1","doi-asserted-by":"publisher","DOI":"10.1002\/cia2.12311"},{"key":"e_1_2_13_122_1","doi-asserted-by":"publisher","DOI":"10.1002\/cia2.12239"},{"key":"e_1_2_13_123_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1402-9645"},{"key":"e_1_2_13_124_1","unstructured":"Gaboriau.Dupilumab and cutaneous lymphoma: Adverse drug reaction or atopic dermatitis course?Available from:https:\/\/onlinelibrary\u2010wiley\u2010com.passerelle.univ\u2010rennes1.fr\/doi\/10.1111\/fcp.12789"},{"key":"e_1_2_13_125_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268"},{"key":"e_1_2_13_126_1","doi-asserted-by":"publisher","DOI":"10.3352\/jeehp.2013.10.12"},{"key":"e_1_2_13_127_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00952-w"},{"key":"e_1_2_13_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2025.03.030"},{"key":"e_1_2_13_129_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16050861"},{"key":"e_1_2_13_130_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.274506"},{"key":"e_1_2_13_131_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004256"},{"key":"e_1_2_13_132_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081931"},{"key":"e_1_2_13_133_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013379"},{"key":"e_1_2_13_134_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2455489"},{"key":"e_1_2_13_135_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.4582"},{"key":"e_1_2_13_136_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2022.4238"},{"key":"e_1_2_13_137_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llac124"},{"key":"e_1_2_13_138_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19408"},{"key":"e_1_2_13_139_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17834"},{"key":"e_1_2_13_140_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01074-z"},{"key":"e_1_2_13_141_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad072"},{"key":"e_1_2_13_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.02.1116"},{"key":"e_1_2_13_143_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1948"},{"key":"e_1_2_13_144_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.0345"},{"key":"e_1_2_13_145_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00139-2025"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70407","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70407","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:59:25Z","timestamp":1785499165000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":144,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/jdv.70407"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70407","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"2025-08-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}